Chronic Inflammation & Autoimmune Program
Targeted immunomodulatory regenerative medicine approach for autoimmune disorders and chronic inflammatory conditions. Harnessing the natural anti-inflammatory power of mesenchymal stem cells.
14+
Years of Clinical Experience
4,850+
Patients Treated Worldwide
UK
UK Corporate Structure
190+
Peer-Reviewed Publications
Immunomodulation Through Regenerative Medicine
Autoimmune diseases occur when the immune system mistakenly attacks healthy tissue. Our Chronic Inflammation & Autoimmune Program uses the immunomodulatory properties of Wharton's jelly-derived MSCs to recalibrate immune function, reduce chronic inflammation, and promote tissue repair — without the systemic suppression caused by conventional immunosuppressant drugs.
Led by Prof. Dr. Erdal Karaöz, this program integrates comprehensive immunological assessment, personalised MSC therapy, and a structured anti-inflammatory lifestyle protocol. With 14+ years of clinical experience and a UK corporate structure, we provide the accountability and transparency that international patients require.
Conditions Treated in This Program
Your Autoimmune Treatment Journey
A comprehensive, evidence-based approach to immune system recalibration
Immunological Assessment
Detailed immune profiling before treatment
- Complete autoimmune panel and inflammatory markers (CRP, ESR, ANA)
- Comprehensive blood work and metabolic panel
- Medical history review by Prof. Dr. Karaöz's team
- Disease activity scoring (DAS28 for RA, SLEDAI for lupus, etc.)
- Current medication review and interaction assessment
- Personalised treatment protocol design
Clinical Evaluation in Istanbul
In-person assessment at Liv Hospital Ulus
- Physical examination and joint assessment
- Additional diagnostics as indicated
- Baseline disease activity documentation
- Nutritional and gut health evaluation
- Care plan confirmation
- Patient education on expected outcomes
MSC Immunomodulation Therapy
Targeted regenerative medicine application for immune recalibration
- GMP-certified Wharton's jelly MSC preparation
- High-dose intravenous MSC infusion (200–300M cells)
- 2–3 infusion sessions across treatment days
- Continuous vital sign monitoring
- Anti-inflammatory adjunctive therapy
- Post-infusion observation and care
Anti-Inflammatory Protocol
Comprehensive lifestyle and nutrition optimisation
- Personalised anti-inflammatory diet plan
- Gut microbiome optimisation guidance
- Stress reduction and cortisol management
- Supplement protocol (vitamin D, omega-3, curcumin)
- Gradual medication tapering plan (with physician oversight)
- Exercise prescription for joint and tissue health
Long-Term Monitoring
12-month structured follow-up program
- Video consultations at 1, 3, 6, and 12 months
- Repeat inflammatory marker testing
- Disease activity re-scoring
- Medication adjustment support
- Lifestyle protocol refinement
- Second treatment cycle evaluation if needed
Immunomodulation Protocol
Our approach targets the root cause of autoimmune dysfunction through cellular-level immune recalibration
High-Dose IV MSC Infusion
200–300 million Wharton's jelly MSCs administered intravenously. MSCs modulate T-cell, B-cell, and dendritic cell function, shifting the immune response from pro-inflammatory (Th1/Th17) to anti-inflammatory (Th2/Treg) pathways.
Sequential Dosing Protocol
Multiple infusions across treatment days allow for sustained immunomodulation. This sequential approach maintains therapeutic MSC levels and enhances the cumulative anti-inflammatory effect.
Exosome Booster (Optional)
MSC-derived exosomes provide additional cell-free immunomodulatory signalling, extending the therapeutic window and providing sustained anti-inflammatory action.
Gut-Immune Axis Support
Since 70% of the immune system resides in the gut, our protocol includes targeted nutrition and microbiome support to complement the systemic immunomodulation achieved through MSC therapy.
Comprehensive Support Framework
Beyond regenerative medicine approach, our autoimmune program integrates multiple supportive interventions
UK-Registered Corporate Structure
StemCell Longevita operates under a UK corporate structure, providing international patients with the governance standards and consumer protections they expect.
- UK-registered company with full corporate transparency
- Contracts governed by English law for international patient protection
- Dedicated UK-based patient coordination and aftercare team
Frequently Asked Questions
Can I continue my current medications during treatment?
Yes, most patients continue their medications during and after MSC therapy. Our medical team reviews your full medication list and advises on any adjustments. Some patients are able to gradually reduce immunosuppressant dosages over the following months under their home physician's supervision.
How do stem cells help autoimmune conditions?
MSCs are powerful immunomodulators. They recalibrate the overactive immune response by promoting regulatory T-cells (Tregs), reducing inflammatory cytokines, and suppressing autoreactive immune cells — without the broad immunosuppression caused by drugs like methotrexate or biologics.
Which autoimmune conditions respond best to MSC therapy?
Clinical evidence is strongest for rheumatoid arthritis, multiple sclerosis, lupus (SLE), and Crohn's disease. We also see promising outcomes in ulcerative colitis, Lyme disease complications, and other inflammatory conditions. Each case is individually assessed.
How long before results become noticeable?
Most autoimmune patients report initial improvements (reduced pain, better energy, decreased flare frequency) within 4–8 weeks. Maximum benefits typically develop over 3–6 months as the immune system recalibrates. Our 12-month follow-up tracks your progress throughout.
Related clinical questions
Where this page sits in the wider picture.